Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool July 20, 2007 Brian Orelli	Baxter's Mixed Message A recall of Baxter BioScience's COLLEAGUE infusion pumps seems to have over-shadowed healthy quarterly earnings reports.
The Motley Fool April 18, 2008 Brian Orelli	Recalls Can't Beat Baxter In spite of charges for two recalls, Baxter posts a decent quarter.
The Motley Fool February 2, 2006 Stephen D. Simpson	AstraZeneca: Of Patents and Pipelines Losing Toprol-XL would be a blow, but not a fatal one. So what to do with AstraZeneca's stock? It might not be as cheap as Pfizer or Abbott Labs, but if the pipeline works out, it still seems like there's money to be made here.
The Motley Fool January 28, 2005 Brian Gorman	Baxter Plods On 2005 looks like another year of transition for Baxter International. The medical products and services concern reported that after currency adjustments, fourth-quarter 2004 revenue of $2.6 billion was essentially flat compared with the same period in 2003.
The Motley Fool October 19, 2007 Brian Orelli	Baxter Gets Pumped Up Medical-device maker Baxter puts in a nice quarter despite two recent FDA recalls.
The Motley Fool April 22, 2005 Brian Gorman	Baxter Is on the Mend The medical products company continues to right itself for a brighter future. The firm's long-term positioning and diversified business may make it worth a closer look.
The Motley Fool November 10, 2005 Stephen D. Simpson	Hospitable Treatment for Hospira Solid margins fuel strong earnings at the hybrid generics - medical distributor. Buying this stock wisely may be the key to good long-term returns.
The Motley Fool November 3, 2011 Dan Caplinger	Has Baxter International Become the Perfect Stock? Baxter needs to keep working on getting its debt levels down and seek out new growth opportunities. With favorable demographic winds at its back, Baxter could be the rare stock to actually reach perfection.
The Motley Fool October 20, 2005 Stephen D. Simpson	Baxter Needs Growth Infusion This is a fine health-care company, but a sluggish top line suggests there are limits to how far it can go. Trading at nearly 20 times forward earnings, it seems like expectations of a growth revival are already in the stock.
The Motley Fool February 29, 2008 Brian Orelli	Bigger Recall, No Big Deal Baxter increases its recall of heparin, but investors shouldn't be that worried.
The Motley Fool January 25, 2008 Brian Orelli	Where the Big Margins Are Drug company investors get to enjoy such high gross margins, but there's generally only so much improvement that a company can make when it starts from such a high point. Take a look at some pharma companies that are succeeding to do just that.
The Motley Fool September 27, 2007 Billy Fisher	Baxter Looking to Bounce Back Shares of the medical device maker finally rebound following a company recall of infusion pumps.
The Motley Fool November 11, 2004 Brian Gorman	Hospira's Possibilities The medical products and services outfit is not flashy, but it may benefit from long-term trends. Their stock may be worth monitoring.
The Motley Fool October 16, 2009 Robert Steyer	Baxter Beats Again -- the Streak Is Alive! The drug, device, and medical services giant beats Wall Street earnings estimates by a penny, but flat sales signal caution.
The Motley Fool May 9, 2006 Stephen D. Simpson	Riding the Hospira Yo-Yo There's a solid foundation on this roller coaster pharmaceutical and drug delivery company. Maybe Hospira's current valuation doesn't make it a "gem," but that's not really within its control.
The Motley Fool April 17, 2009 Robert Steyer	The Steady BAX Beat Baxter International's diverse medical offerings continue to produce prosperity.
The Motley Fool July 17, 2008 Brian Orelli	Investors Yawn at Abbott Labs' Growth Abbott Labs may be firing on all cylinders, but investors were less than impressed with its earnings release
The Motley Fool January 23, 2009 Robert Steyer	BAX to the Future After minding its own business, Baxter International starts thinking about acquisitions again.
The Motley Fool December 23, 2003 Jeff Hwang	Bad, Bad Baxter The medical products company issues its latest in a series of earnings warnings.
The Motley Fool May 9, 2006 Stephen D. Simpson	Will Par Stay in the Fairway? Par Pharmaceutical is relatively unloved; does that mean opportunity or inferiority for investors?
The Motley Fool October 19, 2005 Stephen D. Simpson	ICU, You Look Healthier An incredible third quarter shows what operating leverage can do for this little medical technology company. Investors, take note.
The Motley Fool January 25, 2007 Charly Travers	The Best Drug Stock for 2007 Is ... Is anyone surprised that the largest biotech company in the world, Genentech, came out on top?
The Motley Fool June 17, 2005 W.D. Crotty	Biotech's Apple Dumpling Gang Chiron has made a number of financial and planning mistakes in the production of its flu vaccine.
The Motley Fool August 20, 2007 Brian Orelli	Contracts That Are for the Birds Baxter and GlaxoSmithKline get bird flu vaccine contracts from the U.K. These contracts aren't reasons by themselves to run out and buy the companies' stock, but expanding income sources are almost always a good sign.
The Motley Fool June 29, 2010 Brian Orelli	Redeploying Capital? Investors Hope So. Selling a business unit won't help Abbott Labs diversify.
The Motley Fool October 20, 2009 Brian Orelli	Pfizer Starts the Blame Game Pfizer beat analysts' expectations for both revenue and adjusted earnings, but revenue was still lower than the year-ago quarter. Pfizer has excuses.
The Motley Fool October 18, 2006 Nathan Parmelee	Abbott Puts Its Money on the Table: Fool by Numbers The pharmaceutical released third-quarter 2006 earnings: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights...
The Motley Fool August 26, 2008 Brian Orelli	Baxter Ready to Sop Up Additional Revenue The health-care giant licenses a surgical sponge in clinical development.
The Motley Fool July 13, 2005 Stephen D. Simpson	Is Abbott's Ailment Serious? There's room for improvement at Abbott Labs, but this is one solid and broadly diversified company. Shares aren't a screaming bargain, but the current price-to-earnings ratio really isn't out of line with history.
The Motley Fool April 10, 2008 Brian Orelli	The News for Baxter Just Got Worse These heparin-related deaths aren't associated with Baxter's product, but they still might spell trouble for the company.
The Motley Fool June 1, 2005 Rich Duprey	Able Labs Disabled The generic drug maker recalls its entire inventory over quality concerns. Its stock price cratered 75% the day after the announcement and has since fallen another 30% since then.
The Motley Fool October 19, 2005 Stephen D. Simpson	Abbott Still a Little Pale Perhaps drug and device pipelines, plus margin improvements, can put some color back into the diversified health-care company's stock.
BusinessWeek September 22, 2003	This Baby May Outdo Its Parent Some orphans are better off without their parents -- corporately speaking, that is. My hunch is this may apply to shares due to spring forth next year from health-care giant Abbott Laboratories.
The Motley Fool March 10, 2008 Brian Orelli	Breakup Weighs Down APP It's going to take awhile for APP Pharmaceuticals to reward investors.
The Motley Fool November 8, 2011 Brian Wilson	2 Health-Care Stocks for Times of Uncertainty Just because Abbott and Johnson & Johnson don't undertake as much risk as other health-care giants doesn't mean that shareholders won't see impressive growth in revenues.
The Motley Fool September 28, 2009 Rick Aristotle Munarriz	Abbott Labs Looks Less Lopsided Abbott Labs' $6.6 billion purchase of Solvay's pharmaceuticals business is just what the doctor ordered.
The Motley Fool September 24, 2008 Brian Orelli	Hey, You! Stop! The FDA has ordered Baxter and Hospira to stop making their ophthalmic balanced salt solutions within 60 days.
The Motley Fool January 31, 2006 Stephen D. Simpson	Guidance Puts ICU Medical in the Trauma Ward This oft-volatile stock had a strong fourth quarter, but weak guidance. Even with today's steep drop in price, the shares aren't cheap enough to be interesting.
The Motley Fool August 10, 2010 Seth Jayson	Marginal Performance at Abbott Laboratories Keep your eye on margins.
Chemistry World March 28, 2014 Phillip Broadwith	Baxter aims to divide and conquer US drugmaker Baxter International is spinning off its biopharmaceuticals business to create two independent companies.
The Motley Fool April 4, 2006 Rich Duprey	Chiron's Booster Shot Novartis raises its bid for the biotech a second time, appeasing dissident shareholders.
The Motley Fool October 19, 2004 Rich Duprey	Chiron Crisis Creates Investor Opportunity As flu vaccine maker flames out, other companies may step in to fill the void.
The Motley Fool July 25, 2006 Ryan Fuhrmann	A Steady Heartbeat at Edwards Can Edwards Lifesciences grow enough to justify its stock price?
The Motley Fool November 15, 2011 Dan Caplinger	Has Abbott Labs Become the Perfect Stock? For long-term investors, Abbott's continuing devotion to up its dividend -- its streak now stands at 39 years -- makes a compelling reason to hold onto your shares.
The Motley Fool October 11, 2010 Brian Orelli	What Meridia's Demise Means for Arena, VIVUS, and Orexigen Safety first ... and second ... and third...
The Motley Fool November 9, 2005 Stephen D. Simpson	Fishing for Value at Fisher Even with today's earnings-induced jump, there still might be some value here at researcher Fisher Scientific. Investors, take note.
The Motley Fool April 24, 2007 Ryan Fuhrmann	Earnings-eluting Time at Boston Scientific: Fool by Numbers The medical device firm released first-quarter 2007 results: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights...
The Motley Fool April 20, 2006 Stephen D. Simpson	More Predictable Unpredictability at ICU Hidden beneath all of the volatility is a pretty decent med-tech business. Recent volatility was the kind that investors like. The stock spiked up as earnings exceeded analyst estimates and the business did a fair bit better than management had projected at the end of last quarter.
Pharmaceutical Executive October 1, 2005 Glass & Worrell	Whose Afraid of Authorized Generics Losing a patent challenge lets a generic competitor grab market share and slash branded profits. Sound scary? Ignoring authorized generics is worse.
The Motley Fool October 20, 2011 Brian Orelli	Mini J&J? I Guess Not Abbott says it plans to split in two: drugs in one company, everything else in the other.